Nov 09, 2021

Starpharma to present at Bell Potter Healthcare Conference (ASX Announcement)

Starpharma to present at Bell Potter Healthcare Conference (ASX Announcement)

Melbourne, Australia; 9 November 2021: Starpharma (ASX: SPL, OTCQX: SPHRY) has been invited to present today at the exclusive virtual 2021 Bell Potter Healthcare Conference. The Bell Potter Healthcare Conference showcases leading companies within the Australian healthcare sector and brings together industry leaders with Bell Potter’s network of international and domestic investors, analysts and advisers. The event is available to live-stream via Bell Potter Client Access on 9 – 11 November.

Starpharma will be presenting an abridged presentation focusing on an overview of the business and recent milestones, including:

  • AZD0466, AstraZeneca’s first DEP® oncology product - for which AstraZeneca will present two scientific posters each accompanied by a presentation at the 2021 American Society of Hematology (ASH) Annual Meeting in December.
  • Recent supply arrangements for VIRALEZE™ antiviral nasal spray in Vietnam and Italy, and data published in several leading international journals, Viruses and Nature
  • Update on Starpharma’s other partnered programs, including its DEP® Antibody Drug Conjugates (ADC) programs with Merck & Co Inc., DEP® anti-infective program with Chase Sun, and progress with further commercial discussions with leading companies for additional partnered programs, including in the area of DEP®
  • Brief update on Starpharma’s internal DEP® products, including its phase 2 clinical programs for DEP® docetaxel, DEP® cabazitaxel and DEP®

The presentation can be viewed here.

Download ASX Announcement: Starpharma to present at Bell Potter Healthcare Conference (pdf file, 6MB)

 This contains certain forward-looking statements.